Who
Maricel Apuli
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, BridgeBio Pharma.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $1.2M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 19 Mar 2025
- Last trade
- 16 Aug 2026
- Last filed
- 18 Aug 2026
Companies traded
Activity over time
1 Apr 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Aug 2026filed 18 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $376K4,714 at $79.86 | filing |
| 16 Aug 2026filed 18 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $376K4,714 at $79.86 | filing |
| 30 Jul 2026filed 3 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $160K2,000 at $80.06 | filing |
| 30 Jul 2026filed 3 Aug 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $160K2,000 at $80.06 | filing |
| 16 May 2026filed 19 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $312K4,714 at $66.13 | filing |
| 16 May 2026filed 19 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $312K4,714 at $66.13 | filing |
| 30 Apr 2026filed 4 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $143K2,000 at $71.58 | filing |
| 30 Apr 2026filed 4 May 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $143K2,000 at $71.58 | filing |
| 18 Mar 2026filed 20 Mar 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —14,170 at $0.00 | filing |
| 18 Mar 2026filed 20 Mar 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —14,170 at $0.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $132K2,000 at $66.00 | filing |
| 26 Feb 2026filed 27 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $132K2,000 at $66.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $38K510 at $74.31 | filing |
| 17 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $38K510 at $74.31 | filing |
| 16 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $327K4,349 at $75.25 | filing |
| 16 Feb 2026filed 18 Feb 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $327K4,349 at $75.25 | filing |
| 12 Dec 2025filed 16 Dec 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $151K2,003 at $75.15 | filing |
| 8 Dec 2025filed 10 Dec 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $149K2,000 at $74.26 | filing |
| 16 Nov 2025filed 18 Nov 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $317K4,781 at $66.39 | filing |
| 16 Aug 2025filed 19 Aug 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $245K4,781 at $51.32 | filing |
News
BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Maricel Apuli; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.